{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:09:07Z","timestamp":1790996947812,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T00:00:00Z","timestamp":1649376000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology Case Reports"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.ajoc.2022.101521","type":"journal-article","created":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T11:33:06Z","timestamp":1649935986000},"page":"101521","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Angiographic findings before and after the onset of brolucizumab-associated retinal vascular occlusion and intraocular inflammation"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6458-539X","authenticated-orcid":false,"given":"Sentaro","family":"Kusuhara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Woo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Miki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6464-4302","authenticated-orcid":false,"given":"Makoto","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajoc.2022.101521_bib1","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.ophtha.2019.12.031","article-title":"Brolucizumab: evolution through preclinical and clinical studies and the implications for the management of neovascular age-related macular degeneration","volume":"127","author":"Nguyen","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajoc.2022.101521_bib2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ophtha.2020.06.028","article-title":"HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration","volume":"128","author":"Dugel","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajoc.2022.101521_bib3","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.ophtha.2020.04.017","article-title":"Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab","volume":"127","author":"Baumal","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajoc.2022.101521_bib4","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.ophtha.2020.11.011","article-title":"Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER","volume":"128","author":"Mones","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajoc.2022.101521_bib5","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1177\/2474126420930863","article-title":"Occlusive retinal vasculitis following intravitreal brolucizumab","volume":"4","author":"Witkin","year":"2020","journal-title":"J Vitreoretin Dis"},{"key":"10.1016\/j.ajoc.2022.101521_bib6","article-title":"Brolucizumab-related retinal vasculitis with exacerbation following ranibizumab retreatment: a clinicopathologic case study","volume":"20","author":"Iyer","year":"2020","journal-title":"Am J Ophthalmol Case Rep"},{"key":"10.1016\/j.ajoc.2022.101521_bib7","first-page":"10","article-title":"Inflammatory complications of intravitreal anti-VEGF injections","author":"Cox","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.ajoc.2022.101521_bib8","series-title":"Expert Opinion on Management of Intraocular Inflammation, Retinal Vasculitis, and Vascular Occlusion after Brolucizumab Treatment","author":"Baumal","year":"2020"},{"key":"10.1016\/j.ajoc.2022.101521_bib9","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1007\/s00417-021-05136-w","article-title":"Brolucizumab-related intraocular inflammation in Japanese patients with age-related macular degeneration: a short-term multicenter study","volume":"259","author":"Maruko","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ajoc.2022.101521_bib10","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1038\/s41433-020-01324-w","article-title":"Brolucizumab-foreseeable workflow in the current scenario","volume":"35","author":"Sharma","year":"2021","journal-title":"Eye"},{"key":"10.1016\/j.ajoc.2022.101521_bib11","article-title":"Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study","author":"Bulirsch","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ajoc.2022.101521_bib12","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1001\/jamaophthalmol.2020.7085","article-title":"Early experience with brolucizumab treatment of neovascular age-related macular degeneration","volume":"139","author":"Enriquez","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ajoc.2022.101521_bib13","article-title":"Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration","volume":"18","author":"Haug","year":"2020","journal-title":"Am J Ophthalmol Case Rep"},{"key":"10.1016\/j.ajoc.2022.101521_bib14","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s10384-021-00819-7","article-title":"Three Japanese cases of intraocular inflammation after intravitreal brolucizumab injections in one clinic","volume":"65","author":"Hikichi","year":"2021","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.ajoc.2022.101521_bib15","article-title":"Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations","volume":"18","author":"Jain","year":"2020","journal-title":"Am J Ophthalmol Case Rep"},{"key":"10.1016\/j.ajoc.2022.101521_bib16","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s10384-021-00818-8","article-title":"Three cases of brolucizumab-associated retinal vasculitis treated with systemic and local steroid therapy","volume":"65","author":"Kataoka","year":"2021","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.ajoc.2022.101521_bib17","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1001\/jamaophthalmol.2020.2810","article-title":"Retinal vasculitis after administration of brolucizumab resulting in severe loss of visual acuity","volume":"138","author":"Kondapalli","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ajoc.2022.101521_bib18","doi-asserted-by":"crossref","first-page":"6759","DOI":"10.1038\/s41598-021-86014-7","article-title":"Short-term outcomes of intravitreal brolucizumab for treatment-naive neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy","volume":"11","author":"Matsumoto","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.ajoc.2022.101521_bib19","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4103\/ijo.IJO_3436_20","article-title":"Immediate onset of sterile endophthalmitis with hypopyon after intravitreal Brolucizumab in a case of polypoidal choroidal vasculopathy","volume":"69","author":"Narayanan","year":"2021","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.ajoc.2022.101521_bib20","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000513048","article-title":"Brolucizumab: a newly developed anti-VEGF molecule for the treatment of neovascular age-related macular degeneration","volume":"244","author":"Tadayoni","year":"2020","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.ajoc.2022.101521_bib21","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrclinonc.2009.94","article-title":"Adverse effects of anticancer agents that target the VEGF pathway","volume":"6","author":"Chen","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ajoc.2022.101521_bib22","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1159\/000496197","article-title":"Impaired retinal circulation during axitinib treatment for metastatic renal cell carcinoma","volume":"10","author":"Kimura","year":"2019","journal-title":"Case Rep Ophthalmol"},{"key":"10.1016\/j.ajoc.2022.101521_bib23","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/sj.bjc.6603813","article-title":"Mechanisms of adverse effects of anti-VEGF therapy for cancer","volume":"96","author":"Kamba","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ajoc.2022.101521_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2006.01.027","article-title":"Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration","volume":"113","author":"Rosenfeld","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajoc.2022.101521_bib25","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.ophtha.2020.03.035","article-title":"Efficacy and safety of abicipar in neovascular age-related macular degeneration: 52-week results of phase 3 randomized controlled study","volume":"127","author":"Kunimoto","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajoc.2022.101521_bib26","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/nri1224","article-title":"Ocular immune privilege: therapeutic opportunities from an experiment of nature","volume":"3","author":"Streilein","year":"2003","journal-title":"Nat Rev Immunol"}],"container-title":["American Journal of Ophthalmology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451993622002675?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451993622002675?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T15:03:46Z","timestamp":1762527826000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451993622002675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":26,"alternative-id":["S2451993622002675"],"URL":"https:\/\/doi.org\/10.1016\/j.ajoc.2022.101521","relation":{},"ISSN":["2451-9936"],"issn-type":[{"value":"2451-9936","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Angiographic findings before and after the onset of brolucizumab-associated retinal vascular occlusion and intraocular inflammation","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajoc.2022.101521","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101521"}}